Treat-To-Target: Emergence of Second-Generation CD40L Inhibitors for Treatment of SLE-Identifying Beneficial Patient Candidates for CD40L Inhibitors in a Cross-Sectional SLE Cohort
Scand J Immunol. 2025 Sep;102(3):e70050. doi: 10.1111/sji.70050. ABSTRACT Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterised by heterogeneous […]
